Asthma is an inflammatory disease characterized by recurrent episodes of breathlessness and wheezing. Though inhaled corticosteroids play a vital role in the treatment of asthma, it alone or with long acting beta agonist cannot control asthma symptoms in most of the patients. The present study aims to assess the two controller medications in the form of oral tablets with inhaled corticosteroid combination in controlling forced expiratory volume in one second (FEV1) in mild to moderate persistent asthma patients. A total of 108 patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonary medicine department of a tertiary care hospital. Patients were randomized into two groups viz., Group 1 (n = 54) and Group 2 (n = 54). Group 1 patients received Montelukast and Group 2 patients received Doxofylline. Both the groups received Budesonide inhaler. Pulmonary function test was assessed at the baseline and on follow up days. No significant difference was observed with respect to socioeconomic and educational status of patients between the groups. Significant (p<0.001) improvement in percentage predicted FEV1 after 120 days treatment was observed with both Montelukast and Doxofylline treated groups. There is no statistically significance between the groups. No major adverse events were found during the study period. The study concluded that both controller medications helped in improving lung function.
M.G. Rajanandh, A.D. Nageswari and K. Ilango, 2014. Effect of Two Controller Medications with Inhaled Corticosteroid in Mild to Moderate Persistent Asthma Patients. Journal of Medical Sciences, 14: 81-86.